Czynniki stymulujace wzrost kolonii granulocytarnych [G-CSF] - mozliwosci zastosowania u psow i kotow

• Autorzy: Mroz K , Hildebrand W. , Sadus-Wojciechowska M. , Nicpon J.

Warianty tytułu

EN

Granulocyte colony-stimulating factors [G-CSF] - possibility of use in dogs and cats

• Języki publikacji: PL

Abstrakty

EN

Cancer chemotherapy involves a high risk of complications. Chemotherapy-induced neutropenia is the most common dose-limiting side effect of cancer chemotherapy. The availability of numerous new preparations of hematopoietic growth factors has been increasing over the past decade. The recombinant human granulocyte colony-stimulating factor (rh G-CSF) and other recombinant colony-stimulating factors (r CSF) can reduce the duration of severe neutropenia, the incidence of febrile neutropenia, as well as planned dosing and timing of chemotherapy. The use of filgrastim was described in veterinary medicine in the cases of neutropenia in dogs with hyperestrogenism, parvovirosis, bone marrow apalsia and during oncological treatment and in cats with panleukopenia. The use of colony-stimulating factors is based upon the physiological understanding of the regulation of neutrophil production and deployment in the body under normal condition and in response to infections. It is possible that innovations in the use of these agents will soon lead to further improvements in dog and cat cancer treatment.

Słowa kluczowe

PL

hematopoeza; czynniki stymulujace wzrost kolonii granulocytarnych zob.czynniki G-CSF; czynniki G-CSF; psy; koty; chemioterapia; leczenie wspomagajace

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2009
• Tom: 65
• Numer: 01
• Opis fizyczny: s.20-24,bibliogr.

Twórcy

autor

Mroz K

• Uniwersytet Przyrodniczy we Wroclawiu, pl.Grunwaldzki 47, 50-366 Wroclaw

autor

Hildebrand W.

autor

Sadus-Wojciechowska M.

autor

Nicpon J.

Bibliografia

• 1.Beveridge R. A., Miller J. A., Kales A. N., Binder R. A., Robert N. J., Harvey J. H., Windsor K., Gore I., Cantrell J., Thompson K. A., Taylor W. R., Barnes H. M., Schiff S. A., Shields J. A., Cambareri R. J., Butler T. P., Meister R. J., Feigert J. M., Norgard M. J., Moraes M. A., Helvie W. W., Patton G. A., Mundy L. J., Henry D., Sheridan M. J.: A comparison of efficacy of sargramostin (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosupression. Cancer Invest. 1998, 16, 366-373.
• 2.Bhatt V., Saleem A.: Review: Drug-induced neutropenia-pathophysiology, clinical features, and managment. Ann. Clin. Lab. Sci. 2004, 34, 131-137.
• 3.Biganzoli L., Untch M., Skacel T., Pico J. L.: Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin. Oncol. 2004, 31(Suppl. 8), 27-34.
• 4.Crawford J., Dale D. C., Lyman G. H.: Chemotherapy- induced neutropenia: risk, consequences, and new directions for its management. Cancer 2004, 100, 228-237.
• 5.Dale D. C.: Leczenie neutropenii wywołanej chemioterapią przy użyciu czynników stymulujących wzrost kolonii. Onkologia Prakt. Klin. 2005, 1, 49-53.
• 6.Dmoszyńska A.: Leczenie wspomagające w chorobach rozrostowych układu krwiotwórczego. Acta. Haem. Pol. 1997, 28, suppl. 2, 50-58.
• 7.Fulton R., Ggasper P. W., Oogilvie G. K., Borne T. C., Dornsife R. E.: Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp. Hematol. 1991, 19, 759-767.
• 8.Groblewska M., Mroczko B., Szmitkowski M.: Czynnik stymulujący tworzenie kolonii makrofagowych (M-CSF) i jego zastosowanie w praktyce klinicznej. Pol. Arch. Med. Wewn. 2004, 111, 355-365.
• 9.Hammond W. P., Calba E., Canin A., Rockman H., Souza L. M., Dayton J. E., Dale D. C.: Chronic Neutropenia. J. Clin. Incest. 1991, 87, 704-710.
• 10.Hołowiecki J., Giebel S., Krzemień S., Krawczyk-Kulis M., Jagoda K., Kopera M., Hołowiecka B., Grosicki S., Hellmann A., Dmoszyńska A., Paluszewska M., Robak T., Konopka L., Maj S., Wojnar J., Wojciechowska M., Skotnicki A., Baran W., Cioch M.: G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leukemia Lymphoma 2002, 43, 315-325.
• 11.Huttman A., Schirsafi K., Sreber S., Bojko P.: Comparison of lenograstim and filgrastim: effects on blood cell recovery after high dose chemotherapy and autologous peripheral blood stem cell transplantation. J. Canc. Res. Clin. Oncol. 2005, 131, 152-156.
• 12.Ieishi K., Nomura M., Kawano T., Fujimoto S., Ikefuji H., Noda Y., Nishikado A., Ito S.: The effect of G-CSF in a myocardial ischemia reperfusion model rat. J. Med. Invest. 2007, 54, 177-183.
• 13.Jakimiuk B., Mroczko B., Szmitkowski M.: Czynnik stymulujący kolonie granulocytarne (G-CSF) w praktyce klinicznej. Pol. Arch. Med. Wewn. 2004, 111, 227-235.
• 14.Koc O. N., Gerson S. L., Cooper B. W., Laughlin M., Meyerson H., Kutteh L., Fox M. R., Szekely E. M., Tainer N., Lazarus H. M.: Randomized cross-over trial of progenitor cell mobilization: high dose cyclophosphamide plus granulocyte colony stimulating factor (G-CSF) versus granulocyte-macrophage colony stimulating factor plus G-CSF. J. Clin. Oncol. 2000, 18, 1824-1830.
• 15.Kojima K., Nakashima F., Boku A., Muroishi Y., Nakanishi I., Oda Y.: Clinicopathological study of involvement of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor in non-lymphohematopoietic malignant tumors accompanied by leukocytosis. Histol. Histopathol. 2002, 17, 1005-1016.
• 16.Kraft W., Kuffer M.: Behandlung schwerer Neutropenien bei Hund und Katze mit Filgrastim. Tierärztl. Prax. 1995, 23, 609-613.
• 17.Lothrop C. D. Jr.: Production of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor by carcinomas in a dog and a cat with paraneoplastic leukocytosis. J. Vet. Intern. Med. 1997, 11, 267.
• 18.Mischke R., Barth T., Wohlsein P., Rohn K., Nolte I.: Effect of recombinant human granulocyte colony-stimulating factor (rhGg-CSF) on leukocyte count and survival rate dogs with parvoviral enteritis. Res. Vet. Sci. 2001, 70, 221-225.
• 19.Mróz K., Nicpoń J., Sławuta P.: Neutropenia u psów i kotów - etipatogeneza, objawy kliniczne oraz metody terapii z uwzględnieniem możliwości zastosowania filgrastimu. Medycyna Wet. 2005, 61, 1235-1237.
• 20.Obradovich J. E., Ogilvie G. K., Powers B. E., Boone T.: Evaluation of recombinant canine granulocyte colony stimulating factor as an inducer of granulopoiesis. A pilot study. J. Vet. Intrn. Med. 1991, 5, 75-79.
• 21.Ogilvie G. K.: Hematopoietic growth factors: frontiers for cure. Vet. Clin. North. Am. Small. Anim. Pract. 1995, 25, 1441-1456.
• 22.Quintas-Cardama A., Kantarjian H., O'Brien S., Garcia-Manero G., Rios M. B., Talpaz M., Cortes J.: Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004, 100, 2592-2597.
• 23.Podolak-Dawidziak M., Wojtukiewicz M., Krzemieniecki K., Drosik K., Pawlicki M., Utracka-Hutka B., Krzakowski M.: Aktualne wytyczne dotyczące stosowania cząsteczek pobudzających erytropoezę i hematopoetycznych czynników wzrostu w przebiegu chemioterapii dorosłych chorych na złośliwe nowotwory. Onkologia Prakt. Klin. 2005, 1, 157-164.
• 24.Robak T.: Biologia i farmakologia cytokin. Wyd. Naukowe PWN, Warszawa-Łódź 1995, 1-294.
• 25.Robak T.: Cytokines in the treatment of hematological disorders: Recent Progress and perspectives. Arch. Immunol. Ther. Exp. 1996, 44, 5-9.
• 26.Robak T.: Kliniczne zastosowanie krwiotwórczych czynników wzrostowych. Pol. Tyg. Lek. 1992, 47, 335-368.
• 27.Root R. K., Dale D. C.: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J. Infect. Dis. 1999, 179 (Suppl. 2), 342-352.
• 28.Sharkey L. C., Rosol T. J., Grone A., Ward H., Steinmeyer C.: Production of granulocyte colony-stimulating factor and granulocyte-macrophage colonystimulating factor by carcinomas in a dog and a cat with paraneoplastic leukocytosis. J. Vet. Intern. Med. 1996, 10, 405-408.
• 29.Silva M. G. da, Pimentem P., Carvalhais A., Barbosa I., Machano A., Campilho F., Sousa S. R., Miranda N., da Costa F. L., Campos A., Vaz C. P., Antaz J., Passos-Coehlo J. L.: Ancestim (recombonant human stem cell factor, SCF) in association with filgrastim does not enhance chmotherapy and/or growth factor-induced peripherial blood progenitor cell (PBPC) mobilization in patients with a priori insufficient PBPC collection. Bone Marrow Transplant. 2004, 34, 638-691.
• 30.Skotnicki A. B.: Zastosowanie hematopoetycznych czynników wzrostu (CSF) w praktyce klinicznej. Acta Haem. Pol. 1997, 28, suppl. 2, 59-72.
• 31.Spikermann K., Roesler J., Emmendoerffer A., Elser J., Welfe K.: Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia 1997, 11, 466-478.
• 32.Świeboda-Sadlej A.: Nowe preparaty krwiotwórczych czynników wzrostu. Wspólczesna Onkologia 2004, 8, 96-100.
• 33.Waladkhani A. R.: Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia. Eur. J. Cancer Care 2004, 13, 371-379.
• 34.Walte K., Gabrilove J., Bronchud M. H., Plater E., Morstyn G.: filgrastim (r-metHuG-CSF): The first 10 years. Blood 1996, 6, 1907-1929.
• 35.Westphal S. A.: Recombinant human granulocyte colony-stimulating factor in treatment of methimazole-induced agranulocytosis. Endocr. Pract. 1997, 3, 240-242.
• 36.Wolf T., Densmore J. J.: Pegfilgrastim use during chemotherapy: current and future applications. Curr. Hematol. Rep. 2004, 3, 419-423.
• 37.Vose J. M., Armitage J. O.: Clinical applications of hematopoietic growth factors. J. Clin. Oncol. 1995, 13, 1023-1035.